Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Rachid C. Baz, Thomas G. Martin, III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina, Sundar Jagannath

Blood (2016) 127 (21): 2561–2568.

https://doi.org/10.1182/blood-2015-11-682518

Published: 2016

Includes: Supplemental data

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 303.

https://doi.org/10.1182/blood.V124.21.303.303

Published: 2014

Journal Articles

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Rachid Baz, MD, Thomas G Martin, III, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel Sullivan, M.D., Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2013) 122 (21): 3200.

https://doi.org/10.1182/blood.V122.21.3200.3200

Published: 2013

Journal Articles

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

Rachid Baz, MD, Hui-Yi Lin, PhD, Sung-Soo Yoon, MD, Kihyun Kim, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Dan Sullivan, MD, Hye Jin Kang, Jin Seok Kim, MD, Cheolwon Suh, Je-Jung Lee, MD, PhD, Jeong-A Kim, MD, PhD, Yang Soo Kim, MD, Chang-Ki Min, MD, Jae-Yong Kwak, MD, PhD, Sung-Hyun Kim, MD, PhD, Won Sik Lee, MD, Junshik Hong, MD, Jae Hoon Lee, MD

Blood (2013) 122 (21): 3201.

https://doi.org/10.1182/blood.V122.21.3201.3201

Published: 2013

Journal Articles

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Jiangchuan Tao, MD, PhD, Bijal D. Shah, MD, Xiaohui Zhang, MD, Prerna Rastogi, MBBS, PhD, Jianguo Tao, MD, PhD, Jeffrey E Lancet, MD, Michael Nieder, Hui-Yi Lin, Ph.D, Eduardo M. Sotomayor, MD, Lynn Moscinski, MD, Ling Zhang, MD

Blood (2013) 122 (21): 3875.

https://doi.org/10.1182/blood.V122.21.3875.3875

Published: 2013

Journal Articles

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Blood (2012) 120 (21): 2823.

https://doi.org/10.1182/blood.V120.21.2823.2823

Published: 2012

Journal Articles

Prognostic Significance of VLA4 and CD44 Expression by Flow Cytometry in Multiple Myeloma (MM)

Wasif Riaz, MBBS, John Pham, Ling Zhang, MD, Lynn Moscinski, MD, Lori A Hazlehurst, Ph.D, Michael Emmons, Ph.D, Daniel M Sullivan, MD, Kenneth H Shain, MD, Ph.D, Conor Lynch, Ph.D, Yue Binglin, Hui-Yi Lin, Ph.D, Rachid Baz, MD

Blood (2012) 120 (21): 4975.

https://doi.org/10.1182/blood.V120.21.4975.4975

Published: 2012

Journal Articles

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Beata Holkova, MD, Ashraf Z. Badros, MD, Robert Geller, MD, Peter M. Voorhees, MD, Adriana Zingone, MD, PhD, Neha Korde, MD, Hui-Yi Lin, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Daniel Sullivan, MD, Ola Landgren, MD, PhD, Steven Grant, MD

Blood (2011) 118 (21): 2931.

https://doi.org/10.1182/blood.V118.21.2931.2931

Published: 2011

Journal Articles

Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype

Blood (2010) 116 (21): 612.

https://doi.org/10.1182/blood.V116.21.612.612

Published: 2010

NARROW

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration

Expression Level Of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry Might Correlate With Adverse Clinic Outcome In Adult B- Lymphoblastic Leukemia (B-ALL)

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Prognostic Significance of VLA4 and CD44 Expression by Flow Cytometry in Multiple Myeloma (MM)

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only